MedTrace Logo

Phase I Study of JWCAR029 in Subjects With R/R CLL/SLL

NCT05259813 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2023-11-24

No results posted yet for this study

Summary

This is a Phase I, open-label, single-arm, single center study to assess the safety and efficacy of JWCAR029 in subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Conditions

  • Leukemia, Lymphocytic, Chronic, B-Cell

Interventions

GENETIC

JWCAR029 (Relmacabtagene Autoleucel)

CD19-targeted Chimeric Antigen Receptor (CAR) T Cells

Sponsors & Collaborators

  • The First Affiliated Hospital with Nanjing Medical University

    collaborator OTHER

  • Shanghai Ming Ju Biotechnology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • JianYong Li · The First Affiliated Hospital with Nanjing Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-28
Primary Completion
2023-01-31
Completion
2025-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05259813 on ClinicalTrials.gov